The prognosis of primary disseminated multifocal metastatic Ewing's sarcoma (PDMES) is poor even if a slight improvement has been achieved with high-dose alkylating agent-containing chemotherapy. To enhance treatment efficacy, we assessed the feasibility, safety and efficacy of a tandem high-dose chemotherapy (HDC) regimen. In a single institution, patients with PDMES received six courses of vincristine/ifosfamide/doxorubicin/etoposide induction therapy, followed by high-dose thiotepa, and then melphalan-busulfan, 8 weeks apart. Surgical resection of primary tumour was carried out between the two HDC regimens and 70 days after the last HDC regimen for post-operative radiotherapy or irradiation alone. From October 2002 to 2009, 13 of the 18 consecutive patients with PDMES (72%) received the full treatment programme. The other five patients experienced early progression and died. Among the 13 patients, 11 relapsed after the end of the treatment programme within 6 months (2.2-11.9) from end of therapy. Only two patients are still alive in first complete remission after 9 years. The 3-year event-free survival (EFS) and overall survival (OS) rates were 11 and 22%, respectively. The median EFS and OS duration from the diagnosis were 13.4 and 17.3 months, respectively. Neither major complications nor treatment-related death occurred. The tandem-HDC regimen was feasible, with expected side effects, but it did not improve the outcome of patients with PDMES. 
INTRODUCTION
Ewing sarcoma (ES) is the second most common primary malignant bone tumour in children, adolescents and young adults after osteosarcoma. 1 ES is characterised by a specific translocation t (11;22) and transcript EWS-Fli1. 2 Currently, in the field of multimodality therapy, event-free survival (EFS) rates have increased from 10% to 470% in localised disease. 3, 4 Isolated pulmonary metastatic disease is associated with an EFS rate of 29-52%. 5 Although a slight improvement has been achieved with single high-dose chemotherapy (HDC) regimen, the outcome of patients with primary disseminated multifocal metastatic Ewing's sarcoma (PDMES) remains dismal. The 3-year EFS rate was 27% with the chemotherapy regimen in the R3 arm of the EuroEWING99 (EE99) trial. 6 This regimen comprised a six-course induction chemotherapy of vincristine/ifosfamide/doxorubicin/ etoposide (VIDE), then one course of vincristine/(d)actinomycin/ ifosfamide (VAI) and a single-HDC regimen by busulfan-melphalan (Bu/Mel), as consolidation therapy, followed by autologus peripheral haematopoietic progenitor (APHP) rescue. Prognostic factors (age, initial tumour volume, number of bone metastases, bone marrow and lung involvement) had allowed clinicians to define a prognostic score in this population. 6, 7 The 3-year EFS rate was 50, 25 and 10% for a score of o 3, from 3 to 5 and for a score ⩾ 5, respectively. 6 The benefit of a myeloablative regimen in terms of outcome has been demonstrated in several tumour types with high sensitivity to HDC (for example, high-risk neuroblastomas). 8 In multimetastatic ES, the results of nonrandomised studies evaluating different tandem-HDC regimens remain controversial. [9] [10] [11] [12] Our aim was to determine the feasibility, safety and efficacy of a tandem-HDC programme with high-dose (HD) thiotepa followed by melphalan-busulfan (Mel/Bu).
PATIENTS AND METHODS
From October 2002 to 2009 (after closure of the EE99-R3 arm), patients younger than 25 years presenting with newly diagnosed metastatic ES, other than an isolated pulmonary metastasis (criterion for the EE99-R3 arm), 6 treated in the department of Oncology for child and adolescent at Gustave Roussy, were proposed a tandem-HDC strategy (HD-thiotepa followed by Mel/Bu) as local practice instead of the single-HDC Bu/Mel of the closed EE99-R3 arm trial. The study protocol was approved by the bone tumour committee of the SFCE (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent). A written consent was signed to receive chemotherapy. Disease/patient characteristics, HDC toxicity and outcome data were prospectively collected within our institute graft database. Medical charts were retrospectively reviewed to detail data on toxicity and tumour response to the non-HDC part of the procedure.
The diagnosis of ES was confirmed on the basis of pathological and immunohistochemical features and on the presence of the EWS Fli-1 fusion transcript (except in one patient diagnosed with immunohistochemical features before EWS Fli-1 routine was used). Staging procedures consisted of X-rays, computed tomography (CT) and/or magnetic resonance imaging (MRI) of the primary tumour (PT). The PT volume was measured using the formula defined in the EE99 trial. 6 A chest CT (and/or abdomen and pelvis CT when appropriate) and whole-body technetium bone scintigraphy were used. Confirmatory X-rays and/or MRI for suspected metastases were recommended. Bone marrow (BM) was assessed on the basis of multiple aspirates and two biopsies. When available, a positron emission tomography-computed tomography (PET-CT) was performed.
Induction chemotherapy consisted of six VIDE courses. 13 APHP was the preferred graft source. The recommended cell dose per APHP rescue was ⩾ 3 × 10 6 CD34 + cells/kg of body weight. The collection of APHP was recommended after the fourth VIDE course followed by granulocyte colony-stimulating factor stimulation (5 μg/kg/day). APHP collection was delayed, if necessary, until normalisation of BM cytology. When stem cell collection did not succeed during VIDE induction, one or two cycle(s) of VAI or HD cyclophosphamide were used. When the collection of APHP remained insufficient, autologous BM was collected.
Patients in PR of the primary and metastases after induction chemotherapy and with an adequate stem cell collection proceeded with the tandem-HDC treatment programme; those with progressive disease did not continue the programme. The first cycle consisted of an IV infusion of thiotepa at a dose of 300 mg/m 2 /day over three consecutive days and APHP rescue on the fifth day. The second cycle, recommended 6-8 weeks after the first HDC, consisted of an IV infusion of melphalan at a dose of 140 mg/m 2 on the first day and busulfan at a dose of 0.8-1.2 mg/kg/dose every 6 h over the next 4 days (total 16 doses), with APHP rescue on the seventh day. Anti-pneumocystis prophylaxis was systematic but neither fungal nor viral prophylaxis was used.
Surgical resection of the primary tumour was recommended between the two HDC courses (HDC1 (thiotepa) and HDC2 (Mel/Bu)). If surgery was likely to delay HDC2 beyond 6 weeks, it was postponed 6-8 weeks after the completion of Mel/Bu and stable engraftment. Post-operative radiotherapy or radiotherapy alone was performed at least 70 days after the second APHP rescue. The indication for post-operative radiotherapy depended on the quality of the resection and response to chemotherapy (percentage of remaining viable tumour cells in the primary tumour), in accordance with the EE99 protocol. Local treatment of metastases was not recommended (Figure 1) .
Toxicity was graded according to the CTCAE v3.0 (Common Terminology Criteria for Adverse Events, version 3.0). WHO criteria, 14 based on crosssectional imaging, were used to evaluate efficacy. A CR was defined as the absence of a visible lesion, a PR as lesion shrinkage exceeding 50%, stable disease as lesion shrinkage exceeding 25% but o 50% and progressive disease (PD) as a 25% or more lesion increase, or the appearence of new lesion(s). A metabolic response was assessed by PET-CT in few patients, according to the PERCIST 1.0 Criteria. 15 A good histological response was defined as o5% of viable tumour cells, after surgical resection of the primary tumour. The median intervals to progression or relapse and death were specified relative to the first day of VIDE. OS and EFS were estimated by the Kaplan-Meier method. PD, a second malignancy and death from any cause were considered as events for EFS analyses; otherwise, patients were censored at the date of the last contact. The factors considered for univariate analyses by log-rank tests were sex, age, PT site and volume, sites of metastases, number of bone lesions, lung metastases and intraand extra-osseous involvement. Numerical variables were compared using the Chi 2 -test, and a P-value of o0.05 was considered significant. 6 was four (range 2.5-6).
RESULTS

Patient and disease characteristics
Feasability of the tandem-HDC programme
The main reasons to not proceed with the tandem-HDC programme were early PD at a different step of the programme ( Figure 2 ) associated or not with difficulties in stem cell harvest. All patients received six VIDE courses. Peripheral stem cell collection was performed as recommended after the 4th (n = 3), 5th (n = 5) or 6th VIDE course (n = 3). In one patient without BM disease at diagnosis, the collection was performed after the second VIDE course, without recorded explanation. For three patients, collection was made after additional chemotherapy courses (1VAI n = 1, 2VAI n = 2). The peripheral stem cell harvest was completed by BM stem cell harvest in one patient. In these last three patients, several stem cell harvest attempts failed, and finally the tandem-HDC programme was not performed owing to PD.
Consequently, 15/18 (83%) patients with primary and metastatic PR and an adequate stem cell harvest actually received the HDC1 by HD-thiotepa, with a median time from day 1 of VIDE to day 1 of the HDC1 of 4.8 months (range 4.3-6.8). Two additional patients progressed after HDC1, and thus only 13 effectively received the HDC2 by Mel/Bu, with a median interval of 2.9 months (range 2.0-3.7) from the first HDC.
Overall, only 13 out of the 18 initial patients with PDMES (72%) achieved the full tandem-HDC programme.
Tandem-HDC toxicity There was no treatment-related death ( Table 2 ). The median duration of grade 4 neutropenia (o 500 mm ) was 8 and 10 days, respectively, for thiotepa and Mel/Bu. During aplasia following both HDC courses, 93% of the patients experienced fever (grades 3-4), which was documented in two cases with severe candidosic infections (grade 4). Only one patient developed a refractory disseminated candidosis after Mel/Bu, but died Tandem HDC in metastatic Ewing sarcoma S Loschi et al from a local and metastatic relapse 6 months after the end of the procedure. Three patients developed a varicella-zoster virus (VZV) infection (grade 3) after neutrophil recovery. Grades 3-4 thrombocytopenia ( o50 000 m/m) lasted for a median duration of 37.5 days after Mel/Bu (versus 15 days after thiotepa).Three haemorrhagic complications occurred (retinal haemorrhage (n = 2), grade 3 haemorrhagic cystitis which required a platelet transfusion). 1 Digestive toxicity was predominantly mucositis (n = 6, 46%), lasting a median duration of 6 days after thiotepa and 12 days after Mel/Bu. Grade 1 and grade 3 veno-occlusive disease occurred exclusively after Mel/Bu in two patients (15%). Grade 3 interstitial pneumonia occurred in two patients (15.4%) after Mel/Bu.
Local treatment Fourteen patients (83%) underwent surgical resection of their PT, which was complete in 10/14 cases, with o 10% of residual viable tumour cells in 8/10 evaluated patients (4/5 after thiotepa, and 4/4 after Mel-Bu). Surgery was performed after induction chemotherapy and additional courses owing to stem cell harvest failure in two patients. Six patients were operated on between the two HDC courses, and no surgical complication was observed. In two of them, the local treatment was completed with radiotherapy, either before (2.7 months before the surgical resection of the initially inoperable pelvic primary) or after surgery (1.9 months for a bulky primary retroperitoneal tumour with low chemosensitivity). The remaining six patients underwent surgery after Mel/Bu, and one experienced a surgery-related complication (intraoperative severe haemorrhage), whereupon surgery was discontinued. Local treatment then consisted of 54 Gy of irradiation 3 months after Mel/Bu. One patient had no local treatment of an inoperable pelvic primary that could not be irradiated owing to reports of severe toxicity caused by radiation therapy after Bu/Mel in some French patients at that time. 16 Only one patient underwent surgical excision of a unique skull metastasis, 6 months after Mel/Bu. None had irradiation of metastatic sites.
Efficacy of the tandem-HDC programme After the six VIDE courses, CT/MRI imaging depicted response to induction chemotherapy, with PR of the primary and metastatic sites in all but one patient (94%). Among them, four patients achieved a metabolic CR of metastases, and one of the PT. The last patient had PD. Two other patients progressed after additional VAI courses for stem cell harvest. 
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Thus, all 15 patients who received HDC1 were in PR at primary and metastatic sites, before HD-thiotepa administration. Among them, 13 patients (87%) achieved an objective response to HD-thiotepa at metastatic (n = 12) and at primary (n = 10) sites, including four patients with CR at metastatic sites, whereas two patients progressed. Surgery then permitted six additional CRs at the primary site to be obtained.
The 13 patients who received HDC2 were in CR of the primary and metastases (n = 4), in PR of the primary and metastases (n = 7, including one with a metabolic CR) or in CR of the primary and PR of metastases (n = 2), before Mel/Bu administration. Among them, 12 patients (92%) achieved an objective response to Mel/Bu at metastatic (n = 11) and primary (n = 6) sites and one patient had stable disease. Out of the five patients operated after Mel/Bu, four achieved CR at the primary site and one progressed at the metastatic site immediately after surgery.
Overall, during the treatment programme, 7/18 patients developed early PD (three before first HDC, two after thiotepa and two after Mel/bu) at sites that were involved at diagnosis, and they ultimatelly died. The median survival time was 8 months (range 5.3-9.4) after Day 1 of VIDE and 3.3 months (range 2-4.1) after the diagnosis of PD.
Outcome after the tandem-HDC programme At the end of the full HDC-tandem programme, 11 patients had not progressed. Five patients were in CR at both primary and metastatic sites, four had primary CR and metastatic PR, one had primary PR and metastatic CR and one had primary and metastatic PR (Figure 2) . Nine out of these 11 patients relapsed, with a median delay of 6.2 months (range 2.5-14.1), including 3/5 patients in CR at primary and metastatic sites at the end of the tandem-HDC programme. Patients mainly relapsed at metastatic sites (n = 7/9), with a median interval of 15.3 months (range 13.1-23.3) either at metastatic sites present at diagnosis (n = 5) or not (n = 6). The two patients with isolated local relapse further developed a metastatic relapse. All patients who relapsed died of their disease (Figure 2) .
Overall, the median EFS and OS durations were of 13.5 and 17.3 months, respectively, with all relapses occurring within the first 2 years of the diagnosis. 3-year EFS was 11% and 3-year OS was 22% (Figure 3 ).
Prognostic factors
The small number of patients prohibited a search for prognostic factors. However, two patients (11%) are alive, free of disease, in first CR, with a follow-up of 9 and 9.3 years, respectively. They had presented with a small PT volume (o 200 mL) and multiple bone and pulmonary metastases in both cases, and BM involvement in one. The EE99-R3 risk scores were at 3.5 and 3, respectively. The tandem-HDC strategy had been applied in both of them and a complete PT resection between or after HDC, with a good histological response to chemotherapy. Neither patient had local treatment of metastasis. Both were in CR at primary and metastatic sites at the end of the treatment programme.
DISCUSSION
The results of first-line treatment for PDMES with a single-HDC strategy using Bu/Mel were unsatisfactory. 6 However, some patients appeared to benefit from this strategy (age o14 years; small primary tumour volume o 200 mL; metastatic sites other than bone).
In our study, we addressed, in PDMES, the feasibility, safety and efficacy of a tandem-HDC strategy, with HD thiotepa and then Mel/Bu, which had already been proven to be efficient in other tumour types (for example, high-risk neuroblastoma). 8 We used the EE99-R3 arm treatment backbone 6 with VIDE induction, one VAI, then Mel/Bu HDC with APHP rescue, and replaced the VAI course with HD thiotepa. The objective was to improve the remission status before Mel/Bu consolidation therapy, and ultimately the outcome of PDMES.
We confirmed the feasibility of the tandem-HDC strategy in first-line treatment of PDMES. Toxicities were as expected, comparable to those observed with that strategy in other tumour types, 8 and without major complications compared with those observed in the EE99-R3 arm single-HDC strategy. 6 Haematological toxicity was constant, usually febrile aplasia without documented infection except for two severe candidosic infections. Platelet . Overall and EFS rates of the 18 patients with multimetastatic ES treated by HDC strategy. The overall and EFS rates of the entire population at 3 years from the first day of VIDE were 11 and 22% respectively. EFS, event-free survival; OS, overall survival.
Tandem HDC in metastatic Ewing sarcoma S Loschi et al recovery was longer and visceral toxicities were more frequent after Mel/Bu than after thiotepa (veno-occlusive disease (n = 2), interstitial pneumonia (n = 2) and toxiderma (n = 4)). The use of another alkylating agent (HD thiotepa) before Mel/Bu did not increase the rate of veno-occlusive disease. 17 No treatmentrelated death was observed, although a 24% rate was described in high-risk neuroblastoma treated with this strategy. 8 The tandem-HDC strategy was not stopped owing to toxicity. However, HDC might have hampered surgical resection of the PT, which was stopped once due to haemorrhage.
Unfortunately, the introduction of HD-thiotepa in the EE99-R3 strategy did not significantly improve the outcome of PDMES. Median OS was 17.3 months in our series compared with 19.2 months using the EE99-R3 single-HDC strategy. Although the comparison is historical, the populations were similar in terms of the EE99-R3 risk score (median = 4 (2.5-5) and 3 (0-6) for the tandem-HDC and single-HDC strategy, respectively) and the percentage of patients who actually received Mel/Bu (72% versus 60% for the tandem-HDC and the single-HDC strategy, respectively; P = 0.3). 6 Results of our series were also comparable to previously published studies of tandem-HDC strategies with other alkylating agents and platinum derivatives in primary advanced or relapsed ES, although comparison is rendered difficult by the heterogeneity of the population in the different published series [9] [10] [11] [12] (Table 3) . Our study presents the largest homogeneous cohort of PDMES treated with the same tandem-HDC programme, and with a long median follow-up.
As observed previously with a single- 6 and a tandem-HDC strategy, [9] [10] [11] [12] the main cause of failure of our tandem-HDC strategy was early metastatic progression or relapse, leading to death. Dose-intense chemotherapy appeared to be an important factor in disease control. When chemotherapy was delayed due to stem cell harvest failure (n = 2), metastatic progression occurred. CR before HDC is described as associated with a better outcome. 6 However, the introduction of HD thiotepa was not sufficient to improve the CR rate before Mel/Bu (4/13 = 27% versus 24/169 = 14% in EE99-R3 trial; P = 0.4). Therefore, other strategies to overcome chemoresistance need to be discussed. An option could be to introduce, early during induction therapy, either different chemotherapeutic agents (for example, temozolomide/ irinotecan 18 ) or new targeted therapies (for example, anti-IGF1R antibodies 19 ) that have proved to be efficient in relapsed or refractory ES, or agents under early development (for example, zoledronic acid, PARP inhibitors). 20 To optimise the detection of a good-quality remission before HDC, further investigations are warranted using PET-CT in extra-pulmonary metastatic ES, in a similar manner to MIBG scintigraphy in neuroblastoma. 21 Several studies have shown greater sensitivity of PET-CT for the detection of lymph node or bone metastases, including in ES. 22, 23 The use of PET-CT response (PERCIST 15 ) to guide ES treatment has so far not been evaluated, whereas it is routinely used for this purpose in Hodgkin disease. 24 Early metastatic relapses after Mel/Bu at sites that were not involved at diagnosis, especially in the patient who received local treatment for metastasis, suggests persistent micrometastatic disease, such as that observed in other tumour types. 25 This finding does not argue in favour of local treatment of metastases, although it has been suggested by others for ES and other sarcoma types (for example, rhabdomyosarcoma). 26 Maintenance treatment in PDMES might be discussed to overcome the persistent micrometastasis problem, as these maintenance strategies have proven to be useful in other systemic diseases with prolonged control or definitive cure (for example, 6 months differentiating agent and immunotherapy in high-risk neuroblastoma; 27 18 months metronomic chemotherapy in lymphoblastic lymphoma/leukaemia). 28 In ES, the concept has been validated in animal models; 29, 30 the evaluation of such strategies is ongoing in human trials, with controversial results in relapsed sarcomas. 31   Table 3 . Comparison of populations and survival rates with the EE99-R3 arm and other tandem-HDC strategies in the treatment of ES Our study Ladenstein et al. 6 Burdach et al. 9 Burke et al. 11 Rosenthal et al. 10 Lashkari et al. 12 No PME at the start Tandem HDC in metastatic Ewing sarcoma S Loschi et al
